AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Friday 13 November 2026
News from the 24 hours to Friday morning, 13 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was mostly positive, led by the acquisition of a St. Louis biotech and a favourable kidney result for Ultomiris. Pipeline commentary and an undervalued-stock mention added support, though one report noted mixed FDA signals and the share price looked flat.
What drove it
- Omniose acquisition
- Ultomiris kidney result
- pipeline and FDA signals
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sat 7 Nov | +4.5 | 9 |
| Sun 8 Nov | +6.0 | 7 |
| Mon 9 Nov | +5.3 | 4 |
| Tue 10 Nov | +5.5 | 12 |
| Wed 11 Nov | +6.3 | 22 |
| Thu 12 Nov | +7.5 | 25 |
| Fri 13 Nov | +5.3 | 8 |
8 stories · 8 headlines · strongest first
Pharma and healthcare on 13 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Ultomiris kidney result for AstraZeneca +8.31 headline today · A piece asks whether an Ultomiris kidney win helps AstraZeneca's rare-disease unit. | ||
| +8.3 | Positive kidney trial result for a rare-disease drug. | |
| AstraZeneca acquires US biotech Omniose +7.41 headline today · 21 in all, since 11 November · AstraZeneca acquired the St. Louis biotech Omniose. | ||
| +7.5 | Buys a small biotech, adding to its research capabilities. | |
| AstraZeneca listed among undervalued British stocks +6.71 headline today · AstraZeneca appears in a list of undervalued British stocks. | ||
| +6.7 | Described as undervalued and worth owning. | |
| AstraZeneca pipeline commentary +5.81 headline today · A commentary piece discusses AstraZeneca's pipeline progress. | ||
| +5.8 | Pipeline progress coverage framed positively. | |
| Compugen cites AstraZeneca in Q3 call +3.31 headline today · Compugen's Q3 call highlights mention AstraZeneca among partners. | ||
| +3.3 | Named as partner in another firm's strong earnings call. | |
| FDA panel gives mixed outcome on AstraZeneca cancer drugs −1.71 headline today · 2 in all, since 12 November · A piece describes a split FDA signal for AstraZeneca's cancer pipeline. | ||
| −1.7 | Mixed regulatory signals for its cancer pipeline. | |
| SAP buyback and AstraZeneca bet linked to 28 January 2027 +0.81 headline today · A piece links an SAP buyback and an AstraZeneca bet to one date. | ||
| +0.8 | Investor-focused piece tying a date to the company's strategic move. | |
| AstraZeneca share price technical and quote pieces +0.21 headline today · 3 in all, since 12 November · The stock was consolidating near a resistance level on mixed momentum. | ||
| 0.0 | Technical share price note with mixed momentum. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.